• Written informed consent by and HIPAA authorization for release of personal health information obtained from the research participant. - Able to speak and read English to a sufficient level of fluency to provide informed consent and complete the study questionnaires. - Age ≥ 18 years at the time of consent. - ECOG Performance Status of ≤ 3 within 28 days prior to consent. - Histological or cytologically confirmed urothelial carcinoma. - Patients must be planned to start systemic therapy with enfortumab vedotin - At time of enrollment, patients must be planned to start enfortumab with or without pembrolizumab

Subjects meeting any of the criteria below may not participate in the study: - Inability of the subject to understand and comply with study procedures. - Having previously received enfortumab vedotin - Students/employees of the study institution, pregnant women, prisoners, and institutionalized individuals (to prevent enrollment of vulnerable subjects).